A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome



Status:Recruiting
Conditions:Neurology, Epilepsy
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:2 - 18
Updated:8/13/2016
Start Date:March 2015
End Date:June 2017
Contact:GW Research Medical Information
Email:mailto:medinfo@gwpharm.com
Phone:+44 (0) 1223 266800

Use our guide to learn which trials are right for you!

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome.

To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children
and young adults with Dravet syndrome.

This study is a 1:1:1 randomized, double-blind, 14-week comparison of two Dose Levels of
GWP42003-P versus placebo. A 28-day screening period prior to randomization (to establish
baseline parameters) will precede the treatment period, which will consist of a two-week
titration period followed by a 12-week maintenance period. The study will aim to determine
the efficacy, safety and tolerability of GWP42003-P compared with placebo. The High Dose
Level will be as recommended by the Data Safety Monitoring Committee (DSMC) after assessment
of safety and pharmacokinetic data from Part A of study GWEP1332. The Low Dose Level will be
defined as 50% of the High Dose Level. The first subject will not enroll into this study
until the DSMC has reviewed the safety data from Part A of study GWEP1332.

Following study completion, all subjects will be invited to continue to receive GWP42003-P
in an open label extension (OLE) study (under a separate protocol).

Key Inclusion Criteria:

- Subject must be male or female aged between 2 and 18 years (inclusive).

- Subject must have a documented history of Dravet syndrome which is not completely
controlled by current antiepileptic drugs.

- Subject must be taking one or more antiepileptic drugs at a dose which has been
stable for at least four weeks.

- All medications or interventions for epilepsy (including ketogenic diet and vagus
nerve stimulation) must have been stable for four weeks prior to screening and
subject is willing to maintain a stable regimen throughout the study.

Key Exclusion Criteria:

- Subject has clinically significant unstable medical conditions other than epilepsy.

- Subject has had clinically relevant symptoms or a clinically significant illness in
the four weeks prior to screening or randomization, other than epilepsy.

- Subject is currently using or has in the past used recreational or medicinal
cannabis, or synthetic cannabinoid based medications (including Sativex®) within the
three months prior to study entry and is unwilling to abstain for the duration for
the study.

- Subject has any known or suspected hypersensitivity to cannabinoids or any of the
excipients of the investigational medicinal products.

- There are plans for the subject to travel outside their country of residence during
the study.

- Any history of suicidal behavior or any suicidal ideation of type four or five on the
Columbia-Suicide Severity Rating Scale (Children's) at screening.
We found this trial at
10
sites
Winchester, Virginia 22601
Principal Investigator: Paul Lyons, MD
Phone: +44(0)1223 266800
?
mi
from
Winchester, VA
Click here to add this to my saved trials
740 South Limestone Street
Lexington, Kentucky 40536
Principal Investigator: Siddharth Kapoor, MD
Phone: +44(0) 1223 266800
?
mi
from
Lexington, KY
Click here to add this to my saved trials
3100 SW 62nd Ave
Miami, Florida 33155
(305) 666-6511
Principal Investigator: Ian Miller, MD
Phone: +44 (0) 1223 266800
Miami Children's Hospital Welcome to Miami Children
?
mi
from
Miami, FL
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: David Moore, MD
Phone: +44(0)1223 266800
McFarland Clinic, PC It has been over 65 years since the founders of McFarland Clinic...
?
mi
from
Ames, IA
Click here to add this to my saved trials
Buffalo, New York 14222
Principal Investigator: Arie Weinstock, MD
Phone: +44(0) 1223 266800
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Chesterfield, Missouri 63017
Principal Investigator: William Rosenfeld, MD
Phone: +44(0)1223 266800
?
mi
from
Chesterfield, MO
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Richard Morse, MD
Phone: +44(0)1223 266800
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Sacramento, California 95816
Principal Investigator: Michael Chez, MD
Phone: +44(0)1223 266800
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
St Paul, Minnesota 55102
Principal Investigator: Dimitros Arkilo, MD
Phone: +44(0)1223 266800
?
mi
from
St Paul, MN
Click here to add this to my saved trials
Zwolle,
Phone: +44 (0) 1223 266800
?
mi
from
Zwolle,
Click here to add this to my saved trials